The surprising failures of Novartis's and Novo Nordisk's heart drugs, both targeting 'genetically validated' pathways, have debunked the widely held belief that genetic data guarantees clinical success. This forces a fundamental rethink of using genetics to de-risk massive drug development investments.
Novartis's Lp(a) drug may have failed not because the target is wrong, but because patients were already so well-treated with existing drugs like statins. This highlights a growing challenge: new therapies must demonstrate significant added value over an increasingly effective standard of care.
U.S. biotech investors use China's 'investigator-initiated trials' for quick, early data. However, recent patient deaths in these less-regulated studies are forcing a re-evaluation of this strategy, highlighting the significant safety and ethical trade-offs being made for development speed.
Following the costly trial failures of Novartis and Novo Nordisk, investors are expected to become highly risk-averse toward cardiovascular drug development. This will create a challenging funding environment for startups in the space as capital shifts to less risky therapeutic areas.
Recent patient deaths in trials by Novartis (Switzerland) and in China reveal a reactive, not proactive, disclosure pattern. Companies often only reveal critical safety information after direct inquiry from reporters or analysts, highlighting a widespread transparency issue in the industry.
The FDA's high volume of recent drug approvals, including therapies rejected multiple times, demonstrates that the agency's core review processes can function effectively even without a permanent commissioner. This suggests the institution's operational machinery is resilient to top-level leadership changes.